PPARG and metabolic dysfunction-associated steatohepatitis: Subsequently, SYSU-3d activates the HSF1/PPARγ coactivator-1α (PGC-1α) pathway, increases mitochondrial biogenesis, combats oxidative stress, and alleviates non-alcoholic steatohepatitis (NASH) 191.